Angiotensin converting enzyme inhibitor use soon after renal transplantation: A randomized, double-blinded placebo-controlled safety study

Daniel Glicklich, Roberto Gordillo, Katarina Supe, Raquel Tapia, Robert Woroniecki, Clemencia Solorzano, Maria Coco

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Activation of the renin-angiotensin system (RAS) followed by increased inflammatory cytokines may be important in the pathogenesis of chronic allograft dysfunction. As many renal transplant recipients show chronic changes on biopsy within the first year, early RAS blockade with angiotensin converting enzyme inhibitor (ACEI) could be beneficial. However, it remains unclear that early ACEI use is safe. We conducted a prospective, randomized, placebo-controlled trial to assess the safety of enalapril 5mg during the early post-transplant period. Subjects took the study medication for sixmonths. Primary endpoints were serum potassium (K) >5.9mEq/L and 30% increase in baseline creatinine. A total of 53 subjects were randomized, and of them, 27 received the study drug. Twenty-nine subjects, 14 ACEI and 15 controls, completed the six-month protocol without reaching an endpoint. Patients on ACEI had higher K and higher BUN at sixmonths. Serum creatinine, hematocrit, and urinary protein were not different. There was no difference in urinary TGF-β1. Twenty-four subjects reached study endpoints. When the common clinical endpoints of elevated creatinine and hyperkalemia were combined, ACEI group had significantly increased endpoints vs. control (10/13, 77% vs. 5/11, 45%, p<0.05). We conclude that ACEI use in the early post-transplant period can be safe but patients must be carefully selected and monitored for elevations in serum creatinine and potassium. Whether early ACEI is beneficial in preserving allograft function requires further study.

Original languageEnglish (US)
Pages (from-to)843-848
Number of pages6
JournalClinical Transplantation
Volume25
Issue number6
DOIs
StatePublished - Nov 2011

Fingerprint

Angiotensin-Converting Enzyme Inhibitors
Kidney Transplantation
Placebos
Safety
Creatinine
Renin-Angiotensin System
Allografts
Potassium
Serum
Transplants
Hyperkalemia
Enalapril
Blood Urea Nitrogen
Hematocrit
Randomized Controlled Trials
Cytokines
Kidney
Biopsy
Pharmaceutical Preparations
Proteins

Keywords

  • Angiotensin converting enzyme inhibitor
  • Renal transplant

ASJC Scopus subject areas

  • Transplantation

Cite this

Angiotensin converting enzyme inhibitor use soon after renal transplantation : A randomized, double-blinded placebo-controlled safety study. / Glicklich, Daniel; Gordillo, Roberto; Supe, Katarina; Tapia, Raquel; Woroniecki, Robert; Solorzano, Clemencia; Coco, Maria.

In: Clinical Transplantation, Vol. 25, No. 6, 11.2011, p. 843-848.

Research output: Contribution to journalArticle

Glicklich, Daniel ; Gordillo, Roberto ; Supe, Katarina ; Tapia, Raquel ; Woroniecki, Robert ; Solorzano, Clemencia ; Coco, Maria. / Angiotensin converting enzyme inhibitor use soon after renal transplantation : A randomized, double-blinded placebo-controlled safety study. In: Clinical Transplantation. 2011 ; Vol. 25, No. 6. pp. 843-848.
@article{de19c92e7b4f4b1eb354d51cc8be6c15,
title = "Angiotensin converting enzyme inhibitor use soon after renal transplantation: A randomized, double-blinded placebo-controlled safety study",
abstract = "Activation of the renin-angiotensin system (RAS) followed by increased inflammatory cytokines may be important in the pathogenesis of chronic allograft dysfunction. As many renal transplant recipients show chronic changes on biopsy within the first year, early RAS blockade with angiotensin converting enzyme inhibitor (ACEI) could be beneficial. However, it remains unclear that early ACEI use is safe. We conducted a prospective, randomized, placebo-controlled trial to assess the safety of enalapril 5mg during the early post-transplant period. Subjects took the study medication for sixmonths. Primary endpoints were serum potassium (K) >5.9mEq/L and 30{\%} increase in baseline creatinine. A total of 53 subjects were randomized, and of them, 27 received the study drug. Twenty-nine subjects, 14 ACEI and 15 controls, completed the six-month protocol without reaching an endpoint. Patients on ACEI had higher K and higher BUN at sixmonths. Serum creatinine, hematocrit, and urinary protein were not different. There was no difference in urinary TGF-β1. Twenty-four subjects reached study endpoints. When the common clinical endpoints of elevated creatinine and hyperkalemia were combined, ACEI group had significantly increased endpoints vs. control (10/13, 77{\%} vs. 5/11, 45{\%}, p<0.05). We conclude that ACEI use in the early post-transplant period can be safe but patients must be carefully selected and monitored for elevations in serum creatinine and potassium. Whether early ACEI is beneficial in preserving allograft function requires further study.",
keywords = "Angiotensin converting enzyme inhibitor, Renal transplant",
author = "Daniel Glicklich and Roberto Gordillo and Katarina Supe and Raquel Tapia and Robert Woroniecki and Clemencia Solorzano and Maria Coco",
year = "2011",
month = "11",
doi = "10.1111/j.1399-0012.2010.01372.x",
language = "English (US)",
volume = "25",
pages = "843--848",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Angiotensin converting enzyme inhibitor use soon after renal transplantation

T2 - A randomized, double-blinded placebo-controlled safety study

AU - Glicklich, Daniel

AU - Gordillo, Roberto

AU - Supe, Katarina

AU - Tapia, Raquel

AU - Woroniecki, Robert

AU - Solorzano, Clemencia

AU - Coco, Maria

PY - 2011/11

Y1 - 2011/11

N2 - Activation of the renin-angiotensin system (RAS) followed by increased inflammatory cytokines may be important in the pathogenesis of chronic allograft dysfunction. As many renal transplant recipients show chronic changes on biopsy within the first year, early RAS blockade with angiotensin converting enzyme inhibitor (ACEI) could be beneficial. However, it remains unclear that early ACEI use is safe. We conducted a prospective, randomized, placebo-controlled trial to assess the safety of enalapril 5mg during the early post-transplant period. Subjects took the study medication for sixmonths. Primary endpoints were serum potassium (K) >5.9mEq/L and 30% increase in baseline creatinine. A total of 53 subjects were randomized, and of them, 27 received the study drug. Twenty-nine subjects, 14 ACEI and 15 controls, completed the six-month protocol without reaching an endpoint. Patients on ACEI had higher K and higher BUN at sixmonths. Serum creatinine, hematocrit, and urinary protein were not different. There was no difference in urinary TGF-β1. Twenty-four subjects reached study endpoints. When the common clinical endpoints of elevated creatinine and hyperkalemia were combined, ACEI group had significantly increased endpoints vs. control (10/13, 77% vs. 5/11, 45%, p<0.05). We conclude that ACEI use in the early post-transplant period can be safe but patients must be carefully selected and monitored for elevations in serum creatinine and potassium. Whether early ACEI is beneficial in preserving allograft function requires further study.

AB - Activation of the renin-angiotensin system (RAS) followed by increased inflammatory cytokines may be important in the pathogenesis of chronic allograft dysfunction. As many renal transplant recipients show chronic changes on biopsy within the first year, early RAS blockade with angiotensin converting enzyme inhibitor (ACEI) could be beneficial. However, it remains unclear that early ACEI use is safe. We conducted a prospective, randomized, placebo-controlled trial to assess the safety of enalapril 5mg during the early post-transplant period. Subjects took the study medication for sixmonths. Primary endpoints were serum potassium (K) >5.9mEq/L and 30% increase in baseline creatinine. A total of 53 subjects were randomized, and of them, 27 received the study drug. Twenty-nine subjects, 14 ACEI and 15 controls, completed the six-month protocol without reaching an endpoint. Patients on ACEI had higher K and higher BUN at sixmonths. Serum creatinine, hematocrit, and urinary protein were not different. There was no difference in urinary TGF-β1. Twenty-four subjects reached study endpoints. When the common clinical endpoints of elevated creatinine and hyperkalemia were combined, ACEI group had significantly increased endpoints vs. control (10/13, 77% vs. 5/11, 45%, p<0.05). We conclude that ACEI use in the early post-transplant period can be safe but patients must be carefully selected and monitored for elevations in serum creatinine and potassium. Whether early ACEI is beneficial in preserving allograft function requires further study.

KW - Angiotensin converting enzyme inhibitor

KW - Renal transplant

UR - http://www.scopus.com/inward/record.url?scp=83455235264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83455235264&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2010.01372.x

DO - 10.1111/j.1399-0012.2010.01372.x

M3 - Article

C2 - 21158922

AN - SCOPUS:83455235264

VL - 25

SP - 843

EP - 848

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 6

ER -